首页> 外文期刊>Angiology: the Journal of Vascular Diseases >Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm.
【24h】

Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm.

机译:美托洛尔和地尔硫卓在患有轻度至中度二尖瓣狭窄伴窦性心律的患者中的可靠性和疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

The authors evaluated the effects of beta blockers (metoprolol) and calcium channel blockers (diltiazem) in patients having mild to moderate mitral stenosis (MS) with sinus rhythm. Eighty patients with a complaint of dyspnea with diagnosed MS were included in this study. Patients were randomized into metoprolol and diltiazem groups. The first group received oral diltiazem treatment for 3 months following an i.v. dose of 25 mg diltiazem. The second group received oral metoprolol for 3 months following an i.v. dose of 5 mg metoprolol. All patients performed a treadmill exercise test at the beginning of and after 3 months of treatment. Transthoracic echocardiographic studies were also performed following the i.v. drug administration and after 3 months of treatment. In addition, oxygen uptakes of patients were measured before and after the stress and after 3 months of treatment. Decreases in peak gradient (PG) and mean transmitral gradient (MG) were observed in the metoprolol group after i.v. and oral metoprolol treatment. A prolongation of exercise time in treadmill exercise test (TET) and a decrease in the maximum heart rate after oral metoprolol treatment were noted. Eighteen patients in the metoprolol group had benefited symptomatically from this treatment and complaints of dyspnea were alleviated, whereas no symptomatic relief was seen in the diltiazem group. No significant prolongation was observed in effort times (p>0.05) of the diltiazem group. Transmitral gradients measured via echocardiographic examination did not change (p>0.05). With respect to oxygen uptake rates, a statistically significant decrease was determined in the metoprolol group, whereas no difference was found in diltiazem group. The authors conclude that metoprolol may be useful in patients with MS and can provide symptomatic relief. They did not observe any beneficial effect of diltiazem in these patients.
机译:作者评估了β-受体阻滞剂(美托洛尔)和钙通道阻滞剂(地尔硫卓)在窦性心律轻度至中度二尖瓣狭窄(MS)患者中的作用。本研究纳入了80例因呼吸困难而诊断为MS的患者。将患者随机分为美托洛尔和地尔硫卓组。第一组在静脉注射后接受口服地尔硫卓治疗3个月。剂量为25 mg地尔硫卓。第二组在静脉注射后接受口服美托洛尔治疗3个月。剂量为5 mg美托洛尔。所有患者在治疗开始和治疗三个月后均进行了跑步机运动测试。 i.v.之后也进行了经胸超声心动图研究。药物治疗和治疗3个月后。另外,在压力前后,治疗3个月后测量患者的摄氧量。静脉注射后美托洛尔组观察到峰梯度(PG)和平均透射梯度(MG)降低。和口服美托洛尔治疗。注意到在口服美托洛尔治疗后跑步机运动测试(TET)中的运动时间延长和最大心率降低。美托洛尔组中的18例患者在症状上受益于这种治疗,呼吸困难的症状得到缓解,而地尔硫卓组中没有症状缓解。地尔硫卓组的努力时间未见明显延长(p> 0.05)。通过超声心动图检查测得的透射梯度没有变化(p> 0.05)。关于吸氧率,美托洛尔组确定有统计学意义的下降,而地尔硫卓组没有发现差异。作者得出结论,美托洛尔可能在MS患者中有用,并且可以缓解症状。他们没有观察到地尔硫卓对这些患者有任何有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号